NuCana (NASDAQ:NCNA) Releases Earnings Results

NuCana (NASDAQ:NCNA) announced its earnings results on Thursday. The company reported ($0.10) EPS for the quarter, Zacks reports.

NuCana Stock Performance

Shares of NASDAQ NCNA traded down $0.08 during midday trading on Friday, reaching $3.41. The company’s stock had a trading volume of 48,409 shares, compared to its average volume of 211,498. The company has a market cap of $102,300.00, a P/E ratio of -0.02 and a beta of 1.51. The business’s 50 day moving average price is $4.30 and its two-hundred day moving average price is $13.93. NuCana has a fifty-two week low of $2.78 and a fifty-two week high of $330.00.

Analysts Set New Price Targets

Several equities research analysts have issued reports on NCNA shares. Wall Street Zen upgraded shares of NuCana to a “sell” rating in a research report on Saturday, August 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, NuCana has a consensus rating of “Sell”.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.